United Therapeutics (UTHR) Accumulated Expenses (2009 - 2025)

United Therapeutics has disclosed Accumulated Expenses across 17 years of filings, most recently posting $480.9 million for Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $480.9 million, up 42.07% year-over-year; the trailing twelve-month figure through Dec 2025 was $480.9 million (up 42.07% YoY), and the FY2025 annual result was $480.9 million, up 42.07% from the prior year.
• Accumulated Expenses came in at $480.9 million for Q4 2025 at United Therapeutics, up from $338.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $480.9 million in Q4 2025 to a low of $170.8 million in Q4 2021.
• The 5-year median for Accumulated Expenses is $292.4 million (2023), against an average of $301.7 million.
• Across the five-year window, Accumulated Expenses fell 6.62% in 2021 and surged 42.07% in 2025, its largest moves.
• United Therapeutics' Accumulated Expenses stood at $170.8 million in 2021, then jumped by 32.2% to $225.8 million in 2022, then increased by 29.5% to $292.4 million in 2023, then climbed by 15.77% to $338.5 million in 2024, then soared by 42.07% to $480.9 million in 2025.
• The last three Accumulated Expenses figures came in at $480.9 million (Q4 2025), $338.5 million (Q4 2024), and $292.4 million (Q4 2023), per Business Quant data.